This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
Growing threat of resistant urinary tract infections and dwindling antibiotics
Infections are strengthening as oral antibiotics fail against stubborn UTIs prompting hospital IV treatments. FDA has not approved new oral drugs for resistant UTIs since 2019 while big pharma exits the field, citing weak sales and stewardship limits. Experts urge government action to fix a fragile antibiotic pipeline amid rising resistance.
MENTIONED IN THIS ARTICLE
Centers For Disease Control and Prevention
FDA
Sarah Doernberg
University of California-San Francisco Medical Center
Rebecca Clausen
Durham
North Carolina
U.S
CDC
Big Pharma
Sameer Kadri
National Institutes of Health Clinical Center
Jason Gallagher
Temple University Hospital
Philadelphia
David Shlaes
Pharmaceutical
Kevin Outterson
Boston University
Iterum Therapeutics
Spero Therapeutics
New England Journal of Medicine
Spero
Molly Pam
San Francisco
Pam
Stanford Medical Center
Congress
World Health Organization
United States
Dominic Chan
Legacy Health
Oregon
Chan
Martha Sharan
Medicare
Ted Schroeder
Nabriva
Kadri
NIH
Neil Clancy
Minh-Hong Nguyen
Veterans Affairs
Pittsburgh
Sens
Michael Bennet
D-Corp
Todd Young
R-Ind
Pasteur
Senate